GRS-CDH Binding Screening for Cancer Agent Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an effective approach for screening agents that modulate the binding level of glycyl-tRNA synthetase (GRS) or its fragments with cadherin (CDH) to prevent or treat cancer, as the interaction between these proteins and their role in cancer microenvironments is not fully understood.
Innovation Solution
A method involving measuring the binding affinity between GRS or its fragments and CDH, both with and without test agents, to identify agents that alter this interaction, and assessing apoptosis in CDH-expressing cells to determine their potential cancer-treating efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional cancer screening methods are used, then existing cancer treatments can be evaluated, but the ability to identify agents modulating GRS-CDH interaction is lost
Solution Approach 1:
The patent divides the GRS protein into functional fragments (N-terminal fragment and C-terminal fragment) to independently assess their binding affinities to CDH. This segmentation allows precise measurement of specific binding interactions while simplifying the overall screening process by focusing on discrete functional domains rather than the entire protein complex.
Solution Approach 2:
The patent introduces CDH (cadherin) as an intermediary protein to mediate the interaction between GRS and cancer cells. By measuring binding affinity between GRS fragments and CDH, the method creates a measurable intermediary interaction that reflects the broader cancer treatment mechanism, enabling indirect but accurate screening of therapeutic agents.
2Loss of information
If GRS-CDH interaction is not fully understood, then cancer mechanism research is limited, but developing a screening method requires this knowledge
Solution Approach 1:
The patent performs preliminary characterization of GRS fragments and their binding interactions with CDH before developing the full screening assay. By pre-determining the binding affinities of GRS fragments to CDH and establishing the biological relevance of this interaction, the method creates a foundation that simplifies subsequent screening implementation without requiring complete understanding of all cancer mechanisms.
Solution Approach 2:
The patent changes the measurement parameter from direct cancer cell response to the binding affinity between GRS fragments and CDH. This parameter transformation allows screening to be performed on a more controllable and measurable interaction, reducing the information gap requirement while maintaining relevance to cancer treatment efficacy.
3Reliability
If binding affinity between GRS and CDH is measured, then agent modulation can be identified, but the complexity of protein interaction analysis increases
Solution Approach 1:
The patent extracts and isolates specific functional fragments of GRS (N-terminal and C-terminal fragments) to measure binding affinity with CDH. By taking out only the relevant portions of the protein that mediate the interaction, the method simplifies measurement while maintaining reliability in detecting agent modulation of the GRS-CDH interaction.
Data Source
AI summary
The present invention relates to a novel method of screening an agent for preventing or treating cancer using glycyl-tRNA synthetase (GRS) and cadherin (CDH). More particularly, it relates to a method of screening and test agent which modulates the binding level of GRS or their fragment with CDH. As can be seen foregoing, the present invention relates to a novel use of GRS and CDH and provides a method of screening an agent for preventing or treating cancer. The method may be used for developing novel agent for treatment of various cancer.